Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass

Abstract

Our objective was to compare the predictive value of the well-established tumour marker CA125 with the newer tumour markers tetranectin (TN), OVX1 and CASA in distinguishing benign and malignant pelvic masses in women. Participants included 185 women, 19 years or older, with a pelvic mass planned for surgical exploration. Significantly different CA125 levels were found between benign tumours and localised ovarian cancer (OC), advanced OC and other non-OCs. Significantly different TN levels were found between benign tumours and advanced OC (stage III/IV), between benign tumours and other cancers and between all OCs and other cancers. For CASA, significant differences were found between benign tumours and all OCs as well as advanced OC. No significant differences could be demonstrated for OVX1. Significant correlations for the 44 OC patients were found between CA125, TN and CASA. No significant correlations were found for OVX1, possibly because of the method used for collection and handling of serum samples. None of the new markers had any additional predictive value compared to CA125. TN and CASA levels correlated with FIGO stage and could be used to discriminate between benign and advanced OC. However, in comparison to the performance of CA125, the additional discriminative value of TN and CASA was minor.

Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin‐2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma

“…It is worth emphasizing that, in our patients at the time of testing, no inflammatory disease was detected. Similar to previously published data, 5,7,32 in our study, CA125 sera concentrations were significantly higher in patients with malignant ovarian neoplasms compared with patients who had benign ovarian neoplasms. Elevated sera CA125 levels were detected in only 2 of 32 patients (6%) with benign ovarian neoplasms.…”

“…The concentrations of all studied markers were significantly higher in the circulation of patients who had Stage III-IV disease compared with patients who had Stage I-II disease. However, CA125 sera levels in patients with FIGO Stage I-II disease were relatively higher than the levels reported previously 6,7 and ranged from 12.0 U/mL to 2812.7 U/mL. The patient with the highest CA125 level (2812.7 U/mL) also had a markedly elevated TPS level (313.3 U/L), indicating high proliferative activity in tumor cells.…”

“…[1][2][3][4] CA125 detects Ͼ 80% of advanced ovarian carcinoma but detects a significantly lower fraction of early stage disease. 1,[5][6][7] It also has been reported that CA125 is a better marker for nonmucinous ovarian malignancy compared with mucinous ovarian malignancy. 1,5 The management of patients with epithelial ovarian carcinoma, especially in establishing response to treatment or predicting clinical outcome, can be improved by combining the evaluation of CA125 levels with the evaluation other serum markers.…”

The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma

“…The clinical usefulness of this marker has been commonly accepted especially in monitoring ovarian cancer (16) . However, CA125 antigen structure and its biologic function have not yet been clarified (17) .…”

Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma

“…Three CASA cutoff levels (6.0, 6.5, and 10.0 U/mL) were examined. These cutoff levels selected because they have previously been used in others studies (6.0 and 10.0 U/mL) (13,14,17,20) or because it was the median value in the present patient population (6.5 U/mL). Similarly, several CA125 cutoff levels (35,65,132, and 339 U/mL) were examined.…”